Supplementary Figure 2 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b
Ida H., Shimizu T., Nishino M., Nakamura Y., Yazaki S., Katsuya Y., Sato J., Koyama T., Iwasa S., Sudo K., Kondo S., Yonemori K., Shitara K., Shiono S., Matsuoka D., Yasuda K., Otake Y., Suzuki T., Takase T., Takashima S., Yamaguchi K., Semba T., Yamamoto N.
<p>S2. Linear (A) and Semi-logarithmic (B) Plasma Concentration Profiles of Eribulin After Administration of E7389-LF.</p>